Scolaris Content Display Scolaris Content Display

Daclizumab para la esclerosis múltiple recurrente remitente

Appendices

Appendix 1. Keywords

{daclizumab} OR {antigen} OR {zenapax} OR {dacliximab} OR {monoclonal antibody} OR {monoclonal antibodies} OR {antigens} AND {relapsing remitting} OR {relapsing‐remitting} OR {remitting‐relapsing} OR {remitting relapsing} OR {relapsing} OR {remitting} OR {relapsing AND remitting}

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Safety, Outcome 1 Any adverse event.
Figuras y tablas -
Analysis 1.1

Comparison 1 Safety, Outcome 1 Any adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Safety, Outcome 2 Serious adverse event.
Figuras y tablas -
Analysis 1.2

Comparison 1 Safety, Outcome 2 Serious adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Safety

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Any adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.89, 1.07]

2 Serious adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.29, 4.54]
Figuras y tablas -
Comparison 1. Safety
Ir a la tabla de la revisión